Company / R&D Expense
SUTRO BIOPHARMA, INC. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$252.0M
FY2025
5-year range
$65.6M / $252.0M
FY2021-FY2025
Trend
+83.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 5 consecutive years, from $54M in FY2020 to $252M in FY2025.
Based on SEC 10-K filings.
$252M in FY2025 with a 5-year CAGR of +36.0%.
Improved from $104M to $252M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +48.5%
- 5-Year CAGR
- +36.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- SUTRO BIOPHARMA, INC.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +36.0%, indicating consistent growth.
- In FY2025, r&d expense increased 83.7% year-over-year.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $252.0M | +83.7% |
| FY2024 | $137.2M | +31.4% |
| FY2023 | $104.4M | +35.7% |
| FY2022 | $77.0M | +17.3% |
| FY2021 | $65.6M | +20.9% |
| FY2020 | $54.3M | -0.7% |
| FY2019 | $54.6M | +25.5% |
| FY2018 | $43.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026